Skip to main content

Copanlisib Dosage

Medically reviewed by Drugs.com. Last updated on Oct 27, 2021.

Applies to the following strengths: 60 mg

Usual Adult Dose for Follicular Lymphoma

60 mg via 1-hour IV infusion on Days 1, 8, and 15 of a 28-day treatment cycle on an intermittent schedule (3 weeks on and 1 week off).

Duration of Therapy: Until disease progression or unacceptable toxicity

Comments: Accelerated approval was granted based on overall response rate; continued approval may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Use: Treatment of relapsed follicular lymphoma (FL) in patients who have received at least 2 prior systemic therapies.

Renal Dose Adjustments

Data not available.

Liver Dose Adjustments

Data not available.

Dose Adjustments

CONCOMITANT USE WITH STRONG CYP450 3A INDUCERS: Not recommended.

CONCOMITANT USE WITH STRONG CYP450 3A INHIBITORS: Reduce dose to 45 mg.

TOXICITY MANAGEMENT:
INFECTIONS:

  • Grade 3 or Higher: Withhold this drug until resolution.
  • Suspected Pneumocystis Jiroveci Pneumonia (PJP) Infection of Any Grade: Withhold this drug; if PJP confirmed, treat infection until resolution then resume this drug at previous dose with concomitant PJP prophylaxis.

HYPERGLYCEMIA:
  • Pre-Dose OR Post-Dose Blood Glucose 500 mg/dL or More: Withhold this drug until fasting glucose is 160 mg/dL or less or a random/non-fasting blood glucose of 200 mg/dL or less; then reduce dose:
  • Second Occurrence: Reduce dose from 45 mg to 30 mg and maintain.
  • Post-Dose BP 150/90 or Greater (Non-Life-Threatening):
  • If Recovery Occurs Within 21 Days: Reduce dose from 60 mg to 45 mg OR from 45 mg to 30 mg.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.